The predicted molecular weight of Recombinant Human MCVII is Mr 9.1 kDa.
Predicted Molecular Mass
9.1
Formulation
This recombinant protein was lyophilized from a 0.2 μm filtered solution in 35% acetonitrile (CH3CN) and 0.1% trifluoroacetic acid (TFA).
Storage and Stability
This lyophilized protein is stable for six to twelve months when stored desiccated at -20°C to -70°C. After aseptic reconstitution, this protein may be stored at 2°C to 8°C for one month or at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. See Product Insert for exact lot specific storage instructions.
Country of Origin
USA
Shipping
Next Day Ambient
Applications and Recommended Usage ? (Quality Tested by Leinco)
ELISA Sandwich: This antibody is useful as the capture antibody in a sandwich ELISA. The suggested coating concentration is 5 µg/ml (100 µl/well) µg/ml. Flow Cytometry: PN:A106 Flow Cytometry: It is recommended to use the indirect method for signal enhancement when enumerating cells expressing CXCR5. A suggested method would be to stain cells expressing CXCR5 with approximately 10 µl per test. A typical test sample constitutes approximately 50 µl of packed whole blood or 1 x 105 continuous passage or activated cell cultures that have been centrifuged at 500 X g for five minutes. Labeling of the cells with the biotin conjugate should be followed by PN:A104, resuspended in 200-400 µl of 1X PBS.
Leinco Protein Advisor
Powered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments.
Recombinant Viral MCV-Type II proteins are valuable research tools for studying the biology, immunology, and therapeutic targeting of Molluscum Contagiosum Virus (MCV), particularly its chemokine-like proteins. These reagents enable precise, reproducible assays and mechanistic investigations that are not possible with native viral material alone.
Key scientific applications and advantages include:
Immunological Assays: Recombinant MCV-Type II chemokine-like proteins are used as antigens in ELISA and Western blot assays to detect and quantify antibodies against MCV in human samples, facilitating serological diagnosis and epidemiological studies.
Functional Characterization: Expression of recombinant MCV-Type II proteins allows for detailed analysis of their biological activity, such as their ability to modulate immune cell migration or interfere with host immune responses. This is critical for understanding viral pathogenesis and immune evasion mechanisms.
Therapeutic Targeting: Recombinant proteins provide a platform for screening antiviral compounds or developing therapeutic antibodies that specifically target MCV components, supporting drug discovery and vaccine development.
Genetic and Evolutionary Studies: Recombinant MCV-Type II enables investigation of sequence variation, recombination events, and genotype-specific functions, which are important for understanding viral diversity and evolution.
High Purity and Consistency: Recombinant production ensures high purity (>97%) and batch-to-batch consistency, which is essential for reproducible bioactivity assays and quantitative studies.
Safety and Accessibility: Recombinant proteins eliminate the need to handle infectious virus, reducing biosafety risks and simplifying experimental protocols.
Tool for Mechanistic Studies: Recombinant viral proteins can be used to dissect molecular interactions with host factors, such as chemokine receptors, and to study their effects in cell-based or animal models.
In summary, using recombinant Viral MCV-Type II in research provides a controlled, safe, and versatile platform for advancing knowledge of MCV biology, immune responses, and therapeutic strategies.
Yes, Recombinant Viral MCV-Type II Chemokine-like Protein can be used as a standard for quantification or calibration in ELISA assays, provided it is purified and its concentration is accurately determined.
Key Points Supporting Use as an ELISA Standard:
Purity and Characterization: Recombinant proteins, such as the Viral MCV-Type II Chemokine-like Protein (e.g., R&D Systems 697-M3), are typically produced with high purity (>97%) and are well-characterized, making them suitable for use as standards in immunoassays like ELISA .
Standard Curve Preparation: ELISA standards should ideally be purified proteins, and recombinant proteins are commonly used for this purpose. The standard curve is generated by serial dilution of the recombinant protein to quantify the target analyte in unknown samples [6, 18].
Validation in Assays: Recombinant viral proteins are routinely used in the development and optimization of ELISA assays for both antigen and antibody detection. Their use ensures reproducibility and specificity in quantification [2, 8, 11].
Technical Guidance: ELISA development systems and protocols recommend using recombinant proteins as standards, especially when quantifying specific viral antigens or antibodies .
Practical Considerations:
Concentration Determination: Accurately measure the concentration of the recombinant protein (e.g., by spectrophotometry or HPLC) before preparing the standard curve.
Buffer Compatibility: Ensure the recombinant protein is in a compatible buffer for your ELISA format (e.g., PBS or assay diluent).
Stability: Store the recombinant protein according to manufacturer instructions to maintain activity and avoid degradation.
Conclusion:
Recombinant Viral MCV-Type II Chemokine-like Protein is appropriate for use as a standard in ELISA assays for quantification or calibration, as long as it is properly purified, quantified, and handled. This approach is widely adopted in immunoassay development and validation [6, 9, 18, 19].
Recombinant Viral MCV-Type II Chemokine-like Protein has been validated primarily for bioactivity assays in published research. This includes functional studies to characterize its chemokine-like properties and its role in viral immune evasion.
Key validated applications in published research include:
Bioactivity assays: The recombinant protein has been used to assess its biological activity, particularly its ability to mimic host chemokines and modulate immune responses.
Functional characterization: Studies have cloned and expressed the MCV type II chemokine-like gene to determine its potential role in immune modulation, such as interfering with host chemokine signaling and leukocyte recruitment.
Antibody validation: Biotinylated antibodies against the MCV-type II chemokine-like protein have been validated for use in Western blot (WB) applications, enabling detection and quantification of the protein in research samples.
Additional context:
The protein is often used in in vitro systems to study its effects on immune cell migration and signaling, as well as its potential to inhibit host immune responses, which is a key mechanism of MCV pathogenesis.
While the primary application is bioactivity, the protein may also serve as a tool for screening antiviral compounds or for generating specific antibodies for research use.
No published research was found validating this recombinant protein for use in diagnostic assays, animal models, or therapeutic applications. The main focus remains on bioactivity and functional immunological studies.
To reconstitute and prepare Recombinant Viral MCV-Type II protein for cell culture experiments, follow these best practices based on standard protocols and manufacturer recommendations:
1. Reconstitution Protocol
Buffer: Reconstitute the lyophilized protein in sterile phosphate-buffered saline (PBS) at a concentration of 100 µg/mL. This is the standard recommendation for this protein (as per R&D Systems and similar suppliers).
Temperature: Allow both the vial and the reconstitution buffer to equilibrate to room temperature before opening and adding the buffer.
Centrifugation: Briefly centrifuge the vial (or tap gently) before opening to ensure all lyophilized powder is at the bottom.
Addition: Carefully add the required volume of sterile PBS along the inner wall of the vial to minimize foaming. Do not vortex; instead, let the vial sit at room temperature for 15–30 minutes with gentle agitation (e.g., occasional gentle swirling or pipetting up and down).
Clarity: The solution should be clear when fully dissolved. If particulates remain, do not use the solution.
2. Storage and Handling
Immediate Use: Use the reconstituted protein as soon as possible for optimal activity.
Aliquoting: If not used immediately, aliquot the solution and store at –20°C or –80°C to avoid repeated freeze-thaw cycles, which can degrade protein activity.
Avoid Water: Do not use sterile water for reconstitution unless specifically indicated; PBS is preferred for stability.
3. Dilution for Cell Culture
Dilution Buffer: Dilute the reconstituted protein to the desired working concentration in cell culture medium containing a carrier protein such as 0.1% BSA, 5% HSA, or 10% FBS. This helps prevent protein loss due to adsorption to surfaces.
Do Not Dilute in Water: Diluting directly in water or plain buffer without carrier may lead to protein degradation or loss of activity.
4. Application in Cell Culture
Add to Cells: Add the diluted protein to your cell culture system according to your experimental design.
Controls: Always include appropriate controls (e.g., vehicle-only, untreated cells).
Summary Checklist:
Reconstitute in sterile PBS (100 µg/mL).
Equilibrate vial and buffer to room temperature.
Centrifuge or tap vial before opening.
Add buffer gently along the vial wall.
Allow 15–30 minutes at room temperature for dissolution.
Do not vortex; avoid vigorous shaking.
Aliquot and store at –20°C or –80°C if not used immediately.
Dilute in culture medium with carrier protein before adding to cells.
Always refer to the Certificate of Analysis (CoA) or product datasheet for any protein-specific instructions, as some variants may have unique requirements.
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
